Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
340 Results for "
Integrin beta
" in MedChemExpress (MCE) Product Catalog:
Products (340)
340 Results for "Integrin beta" in MCE Product Catalog:
Cat. No.: HY-184579C
Target:
Research Areas:
DMG-PEG5000-cRGD is a functionalized PEGylated lipid conjugate composed of three modular components: dimyristoylglycerol (DMG) as the lipid anchoring group, a polyethylene glycol (PEG) spacer arm with a molecular weight of 5000 Da, and cyclic RGD peptide (cyclo(Arg-Gly-Asp)) as the terminal targeting/functional ligand. DMG-PEG5000-cRGD can be incorporated into liposomes, lipid nanoparticles (LNPs), or other nanocarriers to confer ligand-directed targeting capability against αvβ3/αvβ5 integrins on tumor vasculature and cancer cell surfaces.
Cat. No.: HY-187237A
Target:
Research Areas:
DPPE-PEG2000-cRGD is a functionalized PEGylated lipid conjugate composed of three modular components: dipalmitoylphosphatidylethanolamine (DPPE) as the lipid anchoring group, a polyethylene glycol (PEG) spacer arm with a molecular weight of 2000 Da, and cyclic RGD peptide (cyclo(Arg-Gly-Asp)) as the terminal targeting/functional ligand. DPPE-PEG2000-cRGD can be incorporated into liposomes, lipid nanoparticles (LNPs), or other nanocarriers to confer ligand-directed targeting capability against αvβ3/αvβ5 integrins on tumor vasculature and cancer cell surfaces.
Cat. No.: HY-187244A
Target:
Research Areas:
DSG-PEG2000-cRGD is a functionalized PEGylated lipid conjugate composed of three modular components: distearoylglycerol (DSG) as the lipid anchoring group, a polyethylene glycol (PEG) spacer arm with a molecular weight of 2000 Da, and cyclic RGD peptide (cyclo(Arg-Gly-Asp)) as the terminal targeting/functional ligand. DSG-PEG2000-cRGD can be incorporated into liposomes, lipid nanoparticles (LNPs), or other nanocarriers to confer ligand-directed targeting capability against αvβ3/αvβ5 integrins on tumor vasculature and cancer cell surfaces.
Cat. No.: HY-P3726
CAS No.: 80755-87-9
Target:
Research Areas:
Cat. No.: HY-164429
CAS No.: 2418533-90-9
VIP236 is a small-molecule drug conjugate targeting αvβ3 integrin. VIP236 achieves tumor homing via specific binding to αvβ3 integrin and delivers its payload to the tumor microenvironment. The linker of VIP236 is cleavable by neutrophil elastase, which is highly expressed in the tumor microenvironment, to release the payload 7-ethylcamptothecin. This payload induces DNA damage by inhibiting topoisomerase 1, thereby exerting anti-tumor effects. VIP236 exhibits excellent plasma stability and tumor targeting property, with a tumor/plasma payload ratio 10-fold higher than that of the single administration. It effectively induces tumor regression, reduces metastasis formation, and shows good tolerance in mouse models. VIP236 has been used in studies related to non-small cell lung cancer, clear cell renal cell carcinoma, colon cancer, triple-negative breast cancer, small cell lung cancer, and metastatic solid tumors .
Cat. No.: HY-D2062
CAS No.: 1448146-89-1
Cat. No.: HY-P700753
Purity: ≥ 95%, as determined by Bis-Tris PAGE.
Synonyms: ITGA2; Alpha 2 Integrin; Prev. CD49B; Very Late Activation Protein 2 Receptor, Alpha-2 Subunit; GPIa; Very Late Activation Receptor Alpha-2 Subunit; CD49 Antigen-Like Family Member B; Human Platelet Alloantigen System 5; Platelet Membrane Glycoprotein Ia
Species:
Mouse
Source:
HEK293
Cat. No.: HY-P703694
Purity: ≥ 95%, as determined by reducing SDS-PAGE.
Synonyms: ITGA2; Alpha 2 Integrin; Prev. CD49B; Very Late Activation Protein 2 Receptor, Alpha-2 Subunit; GPIa; Very Late Activation Receptor Alpha-2 Subunit; CD49 Antigen-Like Family Member B; Human Platelet Alloantigen System 5; Platelet Membrane Glycoprotein Ia
Species:
Cynomolgus
Source:
HEK293
Cat. No.: HY-P992519
Synonyms: ADWA-11
Target:
Research Areas:
Cat. No.: HY-136692
CAS No.: 479203-71-9
Target:
Research Areas:
HMR 1031 is a very late antigen-4 (VLA4, i.e., integrin α4β1) inhibitor, with IC50 values of 0.7 nM and 0.3 nM against VLA-4/VCAM-1 and VLA-4/fibronectin, respectively. HMR 1031 blocks allergen-induced airway responses and airway inflammation in mouse and sheep models. HMR 1031 can be used in asthma-related research .
Cat. No.: HY-189067
Target:
Research Areas:
IP/EP4 receptor agonist-1 is a PGI2 analog and also an IP/EP4 receptor agonist. IP/EP4 receptor agonist-1 inhibits PAR-mediated integrin αIIbβ3 activation, P-selectin exposure, platelet aggregation and thrombus formation. IP/EP4 receptor agonist-1 can be used in research related to pulmonary hypertension .
Cat. No.: HY-P1654A
CAS No.: 3107375-56-1
Cat. No.: HY-P5991
CAS No.: 103951-35-5
Target:
Research Areas:
Cat. No.: HY-107588R
CAS No.: 916734-43-5
Target:
Research Areas:
TC-I 15 (Standard) is the analytical standard of TC-I 15 (HY-107588). This product is intended for research and analytical applications. TC-I 15 (TC-I-15) is a type of allosteric collagen-binding integrin α2β1 inhibitor, and it also inhibits α1β1 and α11β1. TC-I 15 inhibits platelet adhesion to collagen and thrombus deposition. TC-I 15 prevents the formation of a pre-metastatic microenvironment by inhibiting the uptake of cancer-associated fibroblast (CAF) extracellular vesicles (EVs) by lung fibroblasts, which reduces the metastasis of salivary gland adenocystic carcinoma (SACC) to the lungs in mouse models, .
PAWI-2 is a p53-Activator and Wnt Inhibitor. PAWI-2 inhibits β3-KRAS signaling independent of KRAS. PAWI-2 selectively inhibits phosphorylation of TBK1. PAWI-2 activates apoptosis (activation of caspase-3/7), and induces PARP cleavage. PAWI-2 promotes optineurin translocation into the nucleus and causes G2/M arrest. PAWI-2 reverses cancer stemness and overcomes drug resistance in an integrin β3 KRAS-dependent human pancreatic cancer stem cells (hPCSCs). PAWI-2 inhibits growth of tumors from hPCSCs in orthopic xenograft mice model .
Cat. No.: HY-171216
CAS No.: 278598-52-0
Target:
Research Areas:
GW559090 is a selective, competitive, and high-affinity α4 integrin antagonist with a Kd of 0.19 nM for α4β1. GW559090 can effectively block the binding of α4β1 to vascular cell adhesion molecule 1 (VCAM-1) and fibronectin with IC50 values of 7.72 and 8.04 nM. GW559090 also inhibits the interaction between α4β7 and mucosal addressin cell adhesion molecule 1 (MAdCAM-1) (IC50 = 23 nM). GW559090 can inhibit inflammatory infiltration in the eyes, repair the corneal barrier and restore the function of goblet cells. GW559090 can be used for research of Sjögren's syndrome associated dry eye .
Cat. No.: HY-P705486
Purity: ≥ 95%, as determined by reducing SDS-PAGE.
Synonyms: ITGA2; Alpha 2 Integrin; Prev. CD49B; Very Late Activation Protein 2 Receptor, Alpha-2 Subunit; GPIa; Very Late Activation Receptor Alpha-2 Subunit; CD49 Antigen-Like Family Member B; Human Platelet Alloantigen System 5; Platelet Membrane Glycoprotein Ia
Species:
Human
Source:
HEK293
Cat. No.: HY-171331
CAS No.: 2416165-76-7
Target:
Research Areas:
AB-3PRGD2 is a radiotherapeutic agent targeting integrin αvβ3. AB-3PRGD2 shows improved tumor uptake and prolonged tumor retention, leading to significantly enhanced tumor growth suppression. AB-3PRGD2 can remodel the tumor immune microenvironment by upregulating PD-L1 expression and increasing tumor-infiltrating CD8 + T cells .
Cat. No.: HY-187608
CAS No.: 144412-18-0
Target:
Research Areas:
Ro 44-3888 is an orally active and selective GP IIb-IIIa (fibrinogen receptor, integrin αIIbβ3) inhibitor with an IC50 of 1.9 nM against the human target. Ro 44-3888 blocks the binding of fibrinogen to GP IIb-IIIa and inhibits human ADP-induced platelet aggregation. Ro 44‑3888 is formed via the metabolism of the double prodrug Ro 48‑3657 (HY-10309). Ro 44-3888 is used in studies related to arterial thrombosis .
Cat. No.: HY-P10934
CAS No.: 1095009-44-1
Synonyms: LXY2
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
